Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms

This article was originally published in The Pink Sheet Daily

Executive Summary

South Korea's Ministry of Health and Welfare announced measures to drastically cut drug prices, while also committing to support innovation-focused companies through tax credits and preferential pricing, but both domestic and global pharma reacted with strongly worded opposition.
Advertisement

Related Content

Korea's Health Ministry To Unveil Steeper Price Cuts After Patent Loss; Generics Could Be The Big Loser
Korea's Health Ministry To Unveil Steeper Price Cuts After Patent Loss; Generics Could Be The Big Loser
Korea's Health Ministry Gets In The Act To Generate Korean Innovation For U.S. Markets

Topics

Advertisement
UsernamePublicRestriction

Register

PS072661

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel